Immunome Raises $12.2 Million in Additional Series A Financing

Funding allows further development of novel, outcome-based cancer immunotherapy discovery engine

October 6, 2016

Immunome Raises $5 Million Series A Financing to Advance Novel Cancer Immunotherapies

$5 million funded to advance Immunome’s native human cancer antibody platform

April 20, 2016

Immunome Appoints Michael J. Morin, PhD, as President and Chief Scientific Officer

Industry veteran offers more than 25 years in pharmaceutical research and development with a proven track record of developing approvable cancer therapy candidates

March 8, 2016